Get the Stockscreener App
8.255
1.96%
-0.165
Avalo Therapeutics Inc stock is traded at $8.255, with a volume of 5,041.
It is down -1.96% in the last 24 hours and down -1.61% over the past month.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
See More
Previous Close:
$8.42
Open:
$8.17
24h Volume:
5,041
Relative Volume:
0.06
Market Cap:
$82.90M
Revenue:
$1.93M
Net Income/Loss:
$-7.96M
P/E Ratio:
-0.00234
EPS:
-3530.8178
Net Cash Flow:
$-36.78M
1W Performance:
+15.29%
1M Performance:
-1.61%
6M Performance:
-23.57%
1Y Performance:
+85.92%
1-Day Range:
$7.8214
$8.28
1-Week Range:
$7.05
$8.60
52-Week Range:
$4.0101
$34.46
Avalo Therapeutics Inc Stock (AVTX) Company Profile
Name
Avalo Therapeutics Inc
Sector
Industry
Phone
410-522-8707
Address
540 GAITHER ROAD, ROCKVILLE
Compare AVTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVTX
Avalo Therapeutics Inc
|
8.21 | 82.90M | 1.93M | -7.96M | -36.78M | -3,530.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.09 | 119.81B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
667.75 | 73.66B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
658.48 | 39.55B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.12 | 34.55B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.36 | 28.33B | 3.30B | -501.07M | 1.03B | -2.1146 |
Avalo Therapeutics Inc Stock (AVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-24 | Initiated | BTIG Research | Buy |
| Oct-24-24 | Initiated | H.C. Wainwright | Neutral |
| Apr-16-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Sep-24-21 | Initiated | RBC Capital Mkts | Outperform |
Avalo Therapeutics Inc Stock (AVTX) Latest News
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Sees Significant Growth in Short Interest - MarketBeat
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Down 11.8% in January - MarketBeat
(AVTX) Investment Report - Stock Traders Daily
When (AVTX) Moves Investors should Listen - Stock Traders Daily
AVTX (Avalo Therapeutics) Cash From Discontinued Investing Activities : $0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Drops By 11.8% - MarketBeat
Avalo Therapeutics (NASDAQ:AVTX) Trading Up 6.5%Still a Buy? - MarketBeat
Avalo Therapeutics (NASDAQ:AVTX) Stock Price Up 6.5% – Still a Buy? - Defense World
(AVTX) Trading Signals - Stock Traders Daily
Avalo Therapeutics appoints first chief strategy officer - Pennsylvania Business Report
Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer - citybiz
Avalo Therapeutics Names Biogen Veteran Jennifer Riley as Chief Strategy Officer to Lead $10B Market Push - StockTitan
(AVTX) Proactive Strategies - Stock Traders Daily
Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Increases By 340.4% - MarketBeat
BTIG Research Begins Coverage on Avalo Therapeutics (NASDAQ:AVTX) - Defense World
Avalo Therapeutics initiated with a Buy at BTIG - Yahoo Finance
BTIG optimistic on Avalo Therapeutics stock with potential for transformative Phase 2b trial results - Investing.com Canada
(AVTX) Trading Report - Stock Traders Daily
LUCID CAPITAL MARKETS Initiates Coverage of Avalo Therapeutics (AVTX) with Buy Recommendation - MSN
Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Drops By 46.9% - MarketBeat
Avalo Therapeutics (AVTX) Is a Potential Hidden Gem with Significant Risk - TipRanks
Trading (AVTX) With Integrated Risk Controls - Stock Traders Daily
RA Capital Management L.P. Takes Position in Avalo Therapeutics, Inc. (NASDAQ:AVTX) - MarketBeat
Learn to Evaluate (AVTX) using the Charts - Stock Traders Daily
Avalo Therapeutics (FRA:C6K0) Cash From Other Investing Act - GuruFocus.com
Avalo Therapeutics (FRA:C6K0) Cyclically Adjusted PS Ratio : 0.02 (As of Nov. 21, 2024) - GuruFocus.com
REX American Resources Reports Upbeat Earnings, Joins Avalo Therapeutics, RH And Other Big Stocks Moving Higher On Thursday - MSN
(AVTX) Investment Analysis and Advice - Stock Traders Daily
Orbimed Advisors LLC Acquires New Stake in Avalo Therapeutics Inc - GuruFocus.com
Avalo Therapeutics director June Almenoff acquires $12,749 in stock - Investing.com
Avalo Therapeutics Inc (AVTX) Quarterly 10-Q Report - Quartzy
Avalo Therapeutics receives $69.4M in proceeds from full exercise of private placement warrants - MSN
Avalo Therapeutics secures $69.4 million from warrant exercise By Investing.com - Investing.com Australia
Avalo Therapeutics Closes $69.4 Million Financing - citybiz
Avalo Therapeutics receives $69.4M in proceeds from exercise of warrants - TipRanks
Avalo Therapeutics secures $69.4 million from warrant exercise - Investing.com India
Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants - GlobeNewswire
Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants - GlobeNewswire Inc.
Avalo Therapeutics to Present at Upcoming Investor Conferences - The Manila Times
Avalo Therapeutics reports Q3 EPS ($2.83) vs ($22.83) last year - TipRanks
Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates - GlobeNewswire
Where are the Opportunities in (AVTX) - Stock Traders Daily
Pre-market Movers: EVOK, HCTI, GLUE, MNPR... - RTTNews
Avalo Therapeutics (NASDAQ:AVTX) Coverage Initiated at HC Wainwright - Defense World
Avalo Therapeutics begins Phase 2 trial for hidradenitis suppurativa - Investing.com
Avalo Therapeutics maintains Outperform rating from Oppenheimer - Investing.com
Avalo Therapeutics begins Phase 2 trial for hidradenitis suppurativa By Investing.com - Investing.com UK
Avalo Therapeutics Inc Stock (AVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):